Management of drug interactions in patients with HIV

Annals of Pharmacotherapy

Volumn 31, Issue 9, 1997, Pages 1040-1058

  Tseng, Alice Lin In ^a,b   Foisy, Michelle M ^b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Drug interactions; Human immunodeficiency virus

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTIPARASITIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CIDOFOVIR; CLARITHROMYCIN; CLOFAZIMINE; DELAVIRDINE; DIDANOSINE; ETHAMBUTOL; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; INDINAVIR; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG MONITORING; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOSIS; OPPORTUNISTIC INFECTION; PARASITOSIS; PRIORITY JOURNAL;

EID: 0030767715     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100915     Document Type: Article

References (161)

1. Unadkat JD, Agosti JM. Problems in pharmacokinetic investigations in patients with HIV infection. Clin Pharmacokinet 1990;19:172-6.
2. Sheiton J, Morse GD, Hewitt RG. Gastric hypoacidity among HlV-in-fected outpatients (abstract). Presented at the 2nd National Conference on Human Retroviruses, Washington, DC, January 29-February 2, 1995.
3. Martin Z, Ullrich R, Heise W, Bergs C, Líage M, Riecken EO. Malabsorption is found in early stages of HIV infection and independent of secondary infections (abstract). Presented at the 7th International Conference on AIDS, Florence, Italy, June 16-21, 1991:46.
4. Miller TL, Orav EJ, Martin SR, Cooper ER, McIntosh K, Winter HS. Malnutrition and carbohydrate malabsorption in children with vertically transmitted human immunodeficiency virus 1 infection. Gastroenterology 1991;100:1296-302.
5. Greenson JK, Belitsos PC, Yardley JH, Bartler JG. AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea. Ann Intern Med 1991;114:366-72.
6. Harb GE, Jacobson MA. Human immunodeficiency virus infection: does it increase susceptibility to adverse drug reactions? Drug Saf 1993;9:1-8.
7. Koopmans PP, van der Ven A, Vree TB, van der Meer J. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS 1995;9:217-22.
8. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol 1992;5:1237-57.
9. Carr A, Cooper DA, Penny R. Allergic manifestations of human immunodeficiency virus (HTV) infection. J Clin Immunol 1991;11:55-64.
10. Suttmann U, Ockenga J, Selberg O, Hoogestraat O, Deicher H, Muller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:239-46.
11. Lake-Bakaar G, Tom W, Lake-Bakaar D, Gupta N, Beidas S, Elsakr M, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;109:471-3.
12. Chin T. Effects of an acidic beverage (Coca Cola) on the absorption of ketoconazole (abstract). Presented at the 26th Annual Professional Practice Conference, Toronto, Canada, February 5-9, 1995.
13. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919-25.
14. Huang E, Hewitt RG, Shelton M, Morse GD. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 1996;16:222-9.
15. Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-74.
16. Edelstein H, Knight RT. Severe parkinsonism in two AIDS patients taking prochlorperazine (letter). Lancet 1987;2:341-2.
17. Hollander H, Golden J, Mendelson T, Cortland D. Extrapyramidal symptoms in AIDS patients taking low-dose metoclopramide or chlorpromazine (letter). Lancet 1985;2:1186-7.
18. Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Morb Mortal Wkly Rep 1995;44:1-34.
19. Product information. Norvir (ritonavir). North Chicago: Abbott Laboratories, 1996.
20. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamuvidine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995; 333:1662-9.
21. Scheven J, Scheven ML. Interaction between azoles and amphotericin B in the treatment of candidiasis (letter). Clin Infect Dis 1995;20:1079.
22. Pinching AJ, Helbert M, Peddle B, Robinson D, Janes K, Gor D. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. J Infect 1989;18(suppl 1):33-40.
23. Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Drug interactions with zidovudine. AIDS 1993;7:445-60.
24. Veal GJ, Hoggard PG, Barry MG, Khoo S, Back DJ. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation (letter). AIDS 1996;10:546-8.
25. Back D, Haworth S, Hoggard P, Khoo S, Barry M. Drug interactions with d4T phosphorylation in vitro (abstract). Presented at the XI International Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
26. Bailey DG. Food-drug interactions: emphasis on grapefruit juice effects. Can J Clin Pharmacol 1995;2:10-4.
27. Lange D, Hardin J, Heykants J, Ding C, Van De Velde V, Stusser C, et al. The effect of co-administration of a cola beverage on the bioavailability of itraconazole in AIDS patients (abstract). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
28. Neuvonen PJ, Kivisto KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther 1991;50:498-502.
29. Polk RE, Healy DP, Sahai J, Drewal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841-4.
30. Mueller BA, Abel SR, Brierton DG. Fluoroquinolone bioavailability in patients receiving nutritional supplements. Am J Health-Syst Pharm 1995;52:892-3.
31. Sahai J. Avoiding the ciprofloxacin-didanosine interaction (letter). Ann Intern Med 1995;123:394-5.
32. Product information. Invirase (saquinavir mesylate). Mississauga, Canada: Hoffmann-LaRoche Limited, 1996.
33. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
34. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-9.
35. Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine following administration with grapefruit juice. Br J Clin Pharmacol 1993;36:457-9.
36. Benton R, Honig P, Zamani K, Hewett J, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of Qtc (abstract). Clin Pharmacol Ther 1994;55:146.
37. Zhi J, Rakhit A, Patel IH. Effects of dietary fat on drug absorption. Clin Pharmacol Ther 1995;58:487-91.
38. Hughes WT, Gray VL, Gutteridge WE, Latter VS, Pudney M. Efficacy of hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 1990;34:225-8.
39. Hughes WT, Kennedy W, Shenep JL, Flynn PM, Hetherington SV, Fullen G, et al. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis activity: a Phase I study in human immunodeficiency virus (HTV) infected men. J Infect Dis 1991;163:843-8.
40. Metroka CE, McMechan MR, Andrada R, Laubenstein LJ, Jacobus DP. Failure of prophylaxis with dapsone in patients taking dideoxyinosine (letter). N Engl J Med 1991;325:737.
41. Sahai J, Garber G, Gallicano K, Oliveras L, Cameron DW. Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. Ann Intern Med 1995;123:584-7.
42. Hansten PD, Horn JR. Pharmacokinetic drug interaction mechanisms and clinical characteristics. In: Hansten PD, Horn JR, eds. Drug interactions. Vancouver, WA: Applied Therapeutics, 1993.
43. Product information. Crixivan (indinavir sulfate). West Point, PA: Merck & Co., 1996.
44. Coker RJ, Tomlinson DR, Parkin J, Harris JRW, Pinching AJ, Interaction between fluconazole and rifampicin (letter). BMJ 1990;301:818.
45. Apseloff G, Hilligoss DM, Gardner MJ, Henry EB, Inskeep PB, Gerber N, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991;31:358-61.
46. Lee BL, Tauber MG, Sadler B, Goldstein D, Chambers HR. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther 1996;59:14-21.
47. Hochster H, Dieterich D, Bozzette S, Reichman RC, Connor JD, Liebes L, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 1990;113:111-7.
48. Millar AB, Miller RF, Patou G, Mindel A, Marsh R, Semple SJG. Treatment of cytomegalovirus retinitis with zidovudine and ganciclovir in patients with AIDS: outcome and toxicity. Genitourin Med 1990;66:156-8.
49. Gallicano K, Sahai J, Foster B, Bouchard J, Cameron DW. Rifampin decreases zidovudine plasma concentrations in HIV-infected patients (abstract). Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
50. Collaborative AZT Study Group. Tolerance of AZT in association with trimethoprim-sulfamethoxazole, pyrimethamine, or rifampin (abstract). Presented at the IV International Conference on AIDS, Stockholm, Sweden, June 12-16, 1988.
51. Israelski DM, Tom C, Remington JS. Zidovudine antagonizes the action of pyrimethamine in experimental infection with Toxoplasma gondii. Antimicrob Agents Chemother 1989;33:30-4.
52. Gallicano K, Sahai J, Swick L, Seguin I, Pakuts A, Cameron DW. Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21:1008-11.
53. LeLacheur SF, Simon GL. Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. J Acquir Immune Defic Syndr Hum Retrovirol 1991;4:538-9.
54. Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis 1992;14:773-9.
55. Lee BL, Tuber MG, Chambers HR, Gambertoglio J, Delahunty T. The effect of trimethoprim on the pharmacokinetics of zalcitabine in HIV-infected patients (abstract). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
56. Pastore A, Van Cleef G, Risher EJ, Gillum JG, LeBel M, Polk RE. Dideoxycytidine pharmacokinetics and interaction with clarithromycin in patients seropositive for HIV (abstract). Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
57. Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 1991;50:503-7.
58. Data on file. Research Triangle Park, NC: Glaxo Wellcome Inc., 1996.
59. Hardin TC, Sharkey-Mathis PK, Rinaldi MG, Graybill JR. Evaluation of the pharmacokinetic interaction between itraconazole and didanosine in HIV-infected subjects (abstract). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
60. Knupp CA, Brater C, Relue J, Barbhaiya RH. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J Clin Pharmacol 1993;33:912-7.
61. Moreno F, Hardin TC, Rinaldi MG, Graybill JR. Itraconazole-didanosine excipient interaction (letter). JAMA 1993;269:1508.
62. Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993;53:292-7.
63. Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency viras infection. Antimicrob Agents Chemother 1997;41:169-74.
64. Frascino RJ, Gaines Griffy K, Jung D, Yu S. Multiple dose crossover study of iv ganciclovir induction dose (5 mg/kg iv q12h) and didanosine (200 mg po q12h) in HIV-infected persons (abstract). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
65. Gaines K, Wong R, Jung D. Pharmacokinetic interactions with oral ganciclovir: zidovudine, didanosine, probenecid (abstract). Presented at the X International Conference on AIDS, Yokohama, Japan, August 7-12, 1994.
66. Moore KHP, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 1996;59:550-8.
67. Product information. Rescriptor (delavirdine). Kalamazoo, MI: Pharmacia and Upjohn, 1997.
68. Ferry J, Herman B, Cox S, Carlson G, Carberry P. Delavirdine (DLV) and indinavir (IDV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers. Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
69. Ferry J, Schneck D, Carlson G, Carberry P, Della-Coletta A, Gulotti B, et al. Evaluation of the pharmacokinetic (PK) interaction between ritonavir (R) and delavirdine (DLV) in healthy volunteers. Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
70. Cox S, Batts D, Stewart F, Buss N, Brown A, Chambers J, et al. Evaluation of the pharmacokinetic (PK) interaction between saquinavir (SQV) and delavirdine (DLV) in healthy volunteers. Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
71. Product information. Viramune (nevirapine). Ridgefield, CT: Boehringer-Ingelheim Corp., 1997:
72. Gagnier P, Myers M, Lamson M, Greguski R, Love J, Chodakewitz J. Effect of nevirapine (NVP) on pharmacokinetics (PK) of indinavir (IDV) in HIV-1 patients. Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
73. Lamson M, Gagnier P, Greguski R, Myers M, Leonard J, Lauva I, et al. Effect of nevirapine (NVP) on pharmacokinetics (PK) of ritonavir (RTV) in HIV-1 patients. Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
74. Sahai J, Cameron W, Salgo M, Stewart F, Myers M, Lamson M, et al. Drug interaction study between saquinavir (SQV) and nevirapine (NVP). Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
75. Lee CA, Liang BH, Wu EY, Grettenberger HM, Sandoval TM, Zhang KE, et al. Prediction of nelfinavir mesylate (VIRACEPT) clinical drug interactions based on in vitro human P450 metabolism studies. Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
76. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors (letter). Nature 1995;374:569-71.
77. Merrill DP, Manion DJ, Chou TC, Hirsch MS. Protease inhibitor combination regimens against HIV-I in vitro (abstract). Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
78. McCrea J, Buss N, Stone J, Carides A, Dru J, Stewart F, et al. Indinavirsaquinavir single dose pharmacokinetic study (abstract). Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
79. Kerr B, Yuen G, Daniels R, Quart B, Anderson R. Strategic approach to nelfinavir mesylate (NFV) drug interactions involving CYP3A metabolism. Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
80. Kravcik S, Sahai J, Kerr B, Anderson R, Buss N, Seguin I, et al. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients. Presented at the 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
81. Quellet D, Hsu H, Mukherjee D, Locke C, Leonard JM. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin (abstract). Clin Pharmacol Ther 1996;59:143.
82. Kempf D, Marsh K, Denissen J, Kumar G, Rodrigues D, McDonald E, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 (abstract). Presented at the 3rd National Conference on Human Retroviruses and Related Infections, Washington, DC, January 28-February 1, 1996.
83. Hsu A, Granneman GR, Sun E, Chen P, El-Shourbagy T, Locke C, et al. Assessment of single- and multiple-dose interactions between ritonavir and saquinavir (abstract). Presented at the XI International Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
84. Cato A, Qian I, Carothers L, Carlson G, Locke C, Hsu A, et al. Evaluation of the pharmacokinetic interaction between ritonavir and didanosine (abstract). Clin Pharmacol Ther 1996;59:144.
85. Sahai J, Stewart F, Swick L, Gallicano K, Garber G, Seguin I, et al. Rifabutin reduces saquinavir plasma levels in HIV-infected patients (abstract). Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15-18, 1996.
86. Bach MC. Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS (letter). N Engl J Med 1987;317:547.
87. Reines ED, Gross PA. Antiviral agents. Med Clin North Am 1988;72: 691-715.
88. Product information. Vistide (cidofovir). Foster City, CA: Gilead Sciences Inc., 1996:
89. Product information. Cytovene (ganciclovir). Mississauga, Canada: Hoffmann-LaRoche Limited, 1995.
90. Freitas VR, Fraser-Smith EB, Matthews TR. Efficacy of ganciclovir in combination with other antimicrobial agents against cytomegalovirus in vitro and in vivo. Antiviral Res 1993;20:1-12.
91. Faulds D, Heel RC. Ganciclovir - a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39:597-638.
92. Product information. Fungizone intravenous (amphotericin B). Montreal, Canada: Squibb Canada, 1996.
93. Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14:165-74.
94. Product information. Prepulsid (cisapride). Mississauga, Canada: Janssen-Ortho, Inc., 1995.
95. Cobb M, Desai J, Brown LS, Zannikos P, Trapnell C, Rainey P. The effect of fluconazole on the clinical pharmacokinetics of methadone. Presented at the XI International Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
96. Honig PK, Worham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993;53:630-6.
97. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12(suppl 3):S327-33.
98. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-5.
99. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124:573-6.
100. Trapnell CB, Lavelle JP, O'Leary CR, James DS, Li R, Colburn BS, et al. Rifabutin does not alter fluconazole pharmacokinetics (abstract). Clin Pharmacol Ther 1993;52:196.
101. Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916.
102. Foisy MM, Nix D, Middleton E, Kotas T, Symonds WT. The effects of single dose fluconazole versus multiple dose fluconazole (to steady state) on the pharmacokinetics of theophylline in young healthy volunteers (abstract). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
103. Blum RA, D'Andrea DT, Florentine BM, Wilton JH, Hilligoss DM, Gardner MJ, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991;114:755-7.
104. Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991;35:1765-71.
105. Lelawongs P, Barone JA, Colaizzi JL, Hsuan ATM, Mechlinski W, Legendre R, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988;7:228-35.
106. Lavrijsen K, van't Klooster G, Heykants J. The role of CYP3A4 in the in-vitro metabolism of cisapride in human liver microsomes and in-vitro and in-vivo interactions of cisapride with co-administered drugs. Presented at the Pharmacogenetics Conference, Bethesda, MD, May 4-5, 1995.
107. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. JAMA 1993;269:1513-8.
108. Eller MG, Okerholm RA. Pharmacokinetic interaction between terfenadine and ketoconazole (abstract). Clin Pharmacol Ther 1991;49:130.
109. Pilheu JA, Galati MR, Yunis AS, De Salvo MC, Negroni R, Garcia Fernandez JC, et al. Pharmacokinetic interaction of ketoconazole, isoniazid, and rifampicin. Medicina 1989;49:43-7.
110. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med 1984;311:1681-3.
111. Smith AG. Potentiation of oral anticoagulants by ketoconazole. Br Med J 1984;288:188-9.
112. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989;36:423-6.
113. Wishart JM. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol 1987;17:220-3.
114. Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:654-62.
115. Rex J. Itraconazole-digoxin interaction (letter). Ann Intern Med 1992; 116:525.
116. Black PN, Probable interaction between fluoxetine and itraconazole (letter). Ann Pharmacother 1995;29:1048-9.
117. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-3.
118. Crane JK, Shih HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993;95:445-6.
119. Symonds WT, O'Connor G, Nix DE. Focus on itraconazole: a broad-spectrum antifungal agent for treatment of blastomycosis and histoplasmosis. Hosp Form 1993;28:23-33.
120. Smith JA, Hardin TC, Patterson TF, Rinaldi MG, Graybill JR. Rifabutin decreases itraconazole plasma levels in patients with HIV infection (abstract). Presented at the 2nd National Conference on Human Retroviruses and Related Infections, Washington, DC, January 29-February 2, 1995.
121. Yeh J, Soo SC, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole (letter). BMJ 1990;29:301.
122. Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991;35: 1186-90.
123. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993;34:161-2.
124. Honig P, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady state and electrocardiographic parameters. Drug Invest 1994;7:148-56.
125. The Datri Study Group. Coadministration of clarithromycin alters the concentration-time profile of rifabutin (abstract). Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 4-7, 1994.
126. The Datri Study Group. Clarithromycin plus rifabutin for MAC prophylaxis: evidence for a drug interaction (abstract). Presented at the 1st National Conference on Human Retroviruses and Related Infections, Washington, DC, December 12-16, 1993.
127. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
128. Cone LA, Woodward DR, Simmons JC, Sonnenshein MA. Drug interactions in patients with AIDS (letter). Clin Infect Dis 1992;15:1066-8.
129. Mattila MJ, Linnoila MST, Koskinen R. Effect of aluminium hydroxide and glycopyrrhonium on the absorption of ethambutol and alcohol in man. Br J Clin Pharmacol 1978;5:161-6.
130. Hurwitz A, Scholzman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Respir Dis 1974;109:41-7.
131. Valsalan VC, Cooper GL. Carbamazepine intoxication caused with isoniazid. BMJ 1982;285:261-2.
132. Block SH. Carbamazepine-isoniazid interaction. Pediatrics 1982;69: 494-5.
133. Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction. N Engl J Med 1982; 307:1325-7.
134. Patsalos PN, Duncan JS. Antiepileptic drugs. A review of clinically significant drug interactions. Drug Saf 1993;9:156-84.
135. Sarma GR, Kailasam S, Nair NGK, Narayana ASL, Tripathy SP. Effect of prednisone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrob Agents Chemother 1980;18:661-6.
136. Evans ME, Kortas KJ. Potential interaction between isoniazid and selective serotonin-reuptake inhibitors. Am J Health-Syst Pharm 1995;52: 2135-6.
137. Garrelts JC, Godley PJ, Peteried JD, Gerlach EH, Yakshe CC. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother 1990;34:931-3.
138. Nix DE, Watson WA, Handy L, Frost RW, Rescott DL, Goldstein HR. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy 1989;9:377-80.
139. Nix DE, Watson WA, Lener ME, Frost RW, Krol G, Goldstein H, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700-5.
140. Sano M, Kawakatsu K, Ohkita C, Yamamoto I, Takeyama M, Yamashina M, et al. Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans. Eur J Clin Pharmacol 1988;35:161-5.
141. Schwartz J, Jauregui L, Lettieri J, Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. Antimicrob Agents Chemother 1988;32:75-7.
142. Rogge MC, Solomon WR, Sedman AJ, Welling PG, Toothaker RD, Wagner JG. The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition. Clin Pharmacol Ther 1988; 44:579-87.
143. Kamada AK. Possible interaction between ciprofloxacin and warfarin. DICP Ann Pharmacother 1990;24:27-8.
144. Linville T, Matanin D. Norfloxacin and warfarin (letter). Ann Intern Med 1989;110:751-2.
145. Baciewicz AM, Ashar BH, Locke TW. Interaction of ofloxacin and warfarin (letter). Ann Intern Med 1993;119:1223.
146. Sadler BM, Caldwell P, Scott JD, Rogers M, Blum MR. Drug interaction between rifampin and atovaquone in HIV+ asymptomatic volunteers (abstract). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
147. Kucers A, McBennett N. The use of antibiotics: a comprehensive review with clinical emphasis. 4th ed. Philadelphia: JB Lippincott, 1987: 936-9.
148. Kay L, Kampmann JP, Svendsen TL, Vergman B, Hansen JE, Skovsted L, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 1985;20:323-6.
149. Wagner JC. Rifampin-phenytoin drug interaction (abstract). Drug Intell Clin Pharm 1984;18:497.
150. Jain A, Mehta VL, Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tubercle Lung Dis 1993;74:87-90.
151. Falloon J, Lavelle J, Ogata-Arakaki D, Byrne A, Graziani A, Morgan A, et al. Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of Pneumocystis pneumonia. Antimicrob Agents Chemother 1994;38:1580-7.
152. McEvoy GK, ed. American hospital formulary service drug information. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 1995.
153. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986;11:299-315.
154. Lee BL, Medina I, Benowitz NL, Jacob P, Wofsy CB, Mills J. Dapsone, trimethoprim and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with acquired immunodeficiency syndrome: evidence of drug interactions. Ann Intern Med 1989;110:606-11.
155. Product information. Pentacarinat (pentamidine). Montreal, Canada: Rhone-Poulenc Rorer, 1991.
156. Youle MS, Clarbour J, Gazzard B, Ghanas A. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine (letter). Lancet 1988;1:1455-6.
157. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, Lumholtz IB, Arroe M, Abildgaard U, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand 1979;624(suppl):106-10.
158. Wilcox JB. Phenytoin intoxication and cotrimoxazole (letter). N Z Med J 1981;94:235-6.
159. Product information. Daraprim (pyrimethamine). Research Triangle Park, NC: Glaxo Wellcome, 1995.
160. Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. DICP Ann Pharmacother 1990;24:250-1.
161. O'Reilly RA, Motley CH. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Ann Intern Med 1979;91:34-6.